Maxim Group sets $127 target for Gilead Sciences

January 11, 2015 5:59 PM

24 0

Maxim Group sets $127 target for Gilead Sciences

On Friday, Maxim Group issued a research note with target price of $127 for shares of biotechnology major Gilead Sciences. The investment banking firm has given a 'buy' rating for the stock of Gilead Sciences as the company has managed to generate strong sales for Hepatitis C drug Solvadi.

Some other analysts have also weighed in on Gilead Sciences. In a research note on Wednesday, analysts at Morgan Stanley have given 'overweight' rating to shares of Gilead Sciences. Earlier, they had given 'equal weight' to shares of the biotechnology company. Many companies are trying to get approv...

Also read: ZTE shares rise in Hong Kong after clarification of U.S. bill impact

Read more

To category page